COMPANY

CellVax Therapeutics

CellVax Therapeutics has developed a proprietary personalized tumor cell-based cancer immunotherapy platform. From company website Source · Oct 13, 2026

Keywords: cancer Prostate Cancers Prostate Cancer (Adenocarcinoma) Prostate CA Prostate Cancer (Post Prostatectomy) High-risk Prostate Cancer FK-PC101

Location: Miami, FL · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Oct 14, 2024 Trial start Phase 2: FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer source ↗

Upcoming milestones

Feb 2, 2027 (ESTIMATED) · Phase 2 · FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer · NCT06636682

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06636682	FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer	Phase 2	Recruiting	Oct 14, 2024	Feb 2, 2027 (estimated)